A new trading day began on Monday, with Pyxis Oncology Inc (NASDAQ: PYXS) stock price down -6.72% from the previous day of trading, before settling in for the closing price of $1.19. PYXS’s price has ranged from $1.11 to $6.79 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 40.99%. With a float of $42.26 million, this company’s outstanding shares have now reached $59.45 million.
Let’s determine the extent of company efficiency that accounts for 50 employees. In terms of profitability, gross margin is 84.98%, operating margin of -343.24%, and the pretax margin is -293.15%.
Pyxis Oncology Inc (PYXS) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Pyxis Oncology Inc is 28.94%, while institutional ownership is 40.70%. The most recent insider transaction that took place on Nov 26 ’24, was worth 174,364. In this transaction CFO & COO of this company bought 88,850 shares at a rate of $1.96, taking the stock ownership to the 1,199,143 shares.
Pyxis Oncology Inc (PYXS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 40.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.25% during the next five years compared to -118.72% drop over the previous five years of trading.
Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators
Here are Pyxis Oncology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.05, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.30 in one year’s time.
Technical Analysis of Pyxis Oncology Inc (PYXS)
Looking closely at Pyxis Oncology Inc (NASDAQ: PYXS), its last 5-days average volume was 1.08 million, which is a jump from its year-to-date volume of 0.67 million. As of the previous 9 days, the stock’s Stochastic %D was 12.68%. Additionally, its Average True Range was 0.10.
During the past 100 days, Pyxis Oncology Inc’s (PYXS) raw stochastic average was set at 0.00%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.77% in the past 14 days, which was lower than the 117.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4766, while its 200-day Moving Average is $2.9276. However, in the short run, Pyxis Oncology Inc’s stock first resistance to watch stands at $1.1833. Second resistance stands at $1.2567. The third major resistance level sits at $1.2933. If the price goes on to break the first support level at $1.0733, it is likely to go to the next support level at $1.0367. Should the price break the second support level, the third support level stands at $0.9633.
Pyxis Oncology Inc (NASDAQ: PYXS) Key Stats
With a market capitalization of 66.00 million, the company has a total of 59,466K Shares Outstanding. Currently, annual sales are 0 K while annual income is -73,790 K. The company’s previous quarter sales were 0 K while its latest quarter income was -17,300 K.
